The high transduction rate of mSC in mouse, rat and NHP by AAV2/9 prompted us to evaluate its use as a vector to carry a therapeutic tool into defective mSC in CMT1A disease. The gene discussed is MSC; the disease is Charcot-Marie-Tooth disease type 1A.